KOSPIBiotech & Pharma063160

CKD Bio

₩10,760▼ 1.28%2026-11-18 close
Market Cap
₩59B
Turnover
₩42,993,020
Volume
4K
Shares out.
5.5M
PER
—
PBR
0.6×
EPS
-₩3,471
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Microbiome CDMO pivot amid widening losses

CKD Bio is pivoting toward microbiome CDMO and botulinum toxin, but losses have run for five straight quarters through the third quarter of 2026 and the operating loss has widened.

  1. 1

    Operating profit of KRW 11 billion in 2024 turned positive, but 2025 operating profit fell 67.1% to KRW 3.61 billion.

  2. 2

    The operating loss in the third quarter of 2026 was KRW 5.99 billion, wider than a year earlier, and net losses attributable to controlling shareholders over the last four quarters total KRW 19 billion.

  3. 3

    The debt ratio stood at 136.0% at the end of 2025, with total liabilities of KRW 172.8 billion against total equity of KRW 127 billion.

  4. 4

    The microbiome CDMO business rests on 250 to 1,250-liter fermenters and a GMP plant, and past press reports cited a medium-term target of more than KRW 70 billion in annual revenue.

  5. 5

    The next checkpoint is the 2026 annual report, which should show the drivers behind the 2025 revenue decline and the full-year 2026 profit structure.

02

Business structure

CKD Bio is shifting its focus from a probiotics-centered pharmaceutical business toward biopharmaceutical contract development and manufacturing (CDMO) and new drug development. The disclosures do not break out revenue by segment, so no segment shares are given here.

Past press reports said the company operates microbiome fermenters in a 250 to 1,250-liter range for drug substance production.

Its Ansan plant is a GMP facility dedicated to microbiome drugs, capable of producing samples from preclinical work through Phase 2, and the company has highlighted one-stop production from cell banking to drug substance and drug product.

Its customers are mainly domestic biotech firms developing microbiome drugs, and the company said it would prioritize small-scale CDMO demand focused on early clinical samples. Past reports also described a Phase 1 CDMO contract with BFD for a microbiome-based rheumatoid arthritis candidate.

Probiotic sales, including the Lactofit brand, declined after the endemic period, and the company has said it aims to offset that drop with CDMO revenue.

In pharmaceuticals, the botulinum toxin candidate CKDB-501A received domestic Phase 3 IND clearance and is reported to be in joint clinical trials with Chinese partner CUTIA Therapeutics. In competition, Europe-based Bacterra has fermentation capacity of up to 3,500 liters, larger than CKD Bio's 1,250-liter class. Few domestic companies operate microbiome CDMO businesses, which is cited as a point of differentiation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩34.1B-₩1.5B−4.3%
2025Q4₩42.2B₩100M0.3%
2026Q1₩40.7B-₩1.7B−4.2%
2026Q2₩41.1B-₩5B−12.2%
2026Q3₩29.3B-₩6B−20.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩156B-₩14.8B-₩16.7B−9.5%−11.3%111.5%
2023₩160.4B-₩20.2B-₩24.2B−12.6%−19.7%138.8%
2024₩171.8B₩11B₩8.7B6.4%6.6%117.2%
2025₩160.1B₩3.6B-₩2.9B2.3%−2.3%136.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 156 billion in 2022 to KRW 160.4 billion in 2023 (up 2.8% year on year) and KRW 171.8 billion in 2024 (up 7.1%), then fell 6.8% to KRW 160.1 billion in 2025. Among 2022 to 2025, 2024 was the largest year and 2022 the smallest.

An operating loss of KRW 14.8 billion in 2022 and KRW 20.2 billion in 2023 widened the deficit, before operating profit of KRW 11 billion in 2024 marked a turn to profit. Operating profit then fell 67.1% year on year to KRW 3.61 billion in 2025.

Operating margin ran at -9.5% in 2022, -12.6% in 2023, 6.4% in 2024 and 2.3% in 2025. Net profit attributable to controlling shareholders moved from a loss to KRW 8.7 billion in 2024 and back to a net loss of KRW 2.89 billion in 2025.

Net profit including non-controlling interests matched the controlling-shareholder figure in each year from 2022 to 2025. Operating cash flow was -KRW 3.2 billion in 2022, -KRW 7.22 billion in 2023, KRW 14 billion in 2024 and -KRW 4.14 billion in 2025.

Quarterly, an operating loss of KRW 1.47 billion in the third quarter of 2025 was followed by a KRW 109 million operating profit in the fourth quarter, but losses returned with KRW 1.71 billion in the first quarter of 2026, KRW 5 billion in the second and KRW 5.99 billion in the third.

Third-quarter 2026 revenue of KRW 29.3 billion fell 28.6% from the prior quarter and 14.0% from a year earlier. Net losses attributable to controlling shareholders over the last four quarters total KRW 19 billion. Past press reports linked the widening 2022 loss to botulinum toxin and microbiome R&D spending.

The drivers of the 2026 quarterly losses need to be traced through cost lines in the quarterly reports, and one-off items cannot be separated from the disclosed figures alone.

05

Industry analysis

Microbiome therapeutics and CDMO are a small market where few companies have both production capacity and fermentation process experience. Past reports cited an analysis that more than 500 companies are developing microbiome drugs worldwide, but only about 30 have entered clinical trials.

Industry observers expect CDMO demand to grow as more of these companies enter the clinic. Interest also rose after Rebyota, a microbiome therapy, received FDA approval.

Domestic developers that rely on overseas CDMOs have cited waits of about 18 months before production, which is one reason given for demand for domestic manufacturing. The company has said that about 90% of global microbiome CDMO revenue comes from North America and has described overseas expansion as essential.

In competition, Bacterra has up to 3,500 liters of drug substance capacity, while CKD Bio operates 1,250-liter-class equipment. Large biologics CDMOs such as Samsung Biologics differ in production scale and product scope, which limits direct comparison.

The position of the cycle can be gauged by whether the number of companies entering the clinic and overseas contract wins are rising.

06

Outlook

The medium-term target for microbiome CDMO that the company cited in past press reports is annual revenue of more than KRW 70 billion. Progress toward that target should be tracked in the annual report, which breaks out product sales, and read alongside total 2025 revenue falling to KRW 160.1 billion.

The overseas expansion goal was cited in past reports as 2024, so confirmed overseas contract wins are central to whether that goal is met.

The botulinum toxin candidate CKDB-501A has domestic Phase 3 IND clearance and is reported to be in joint trials with Chinese partner CUTIA Therapeutics, a structure described as sharing clinical costs. The timing of results depends on company disclosures.

With an operating loss of KRW 5.99 billion in the third quarter of 2026 and net losses attributable to controlling shareholders of KRW 19 billion over the last four quarters, the key variable is whether CDMO revenue growth narrows the losses.

The next checkpoint is the 2026 annual report, which will show product-level sales and the R&D trend. The 2027 first-quarter report will show whether the loss run that began in the third quarter of 2025 ends.

07

Valuation

PER
—
PBR
0.6×
ROE
-16.0%
EPS
-₩3,471
BPS
₩19,862
Dividend per share
₩0

Because net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. Earnings capacity weakened from 2025 after profitability in 2024, and quarterly losses have persisted into 2026. On a price-to-book basis, the share price trades at a discount to net asset value.

The debt ratio of 136.0% at the end of 2025, with total liabilities of KRW 172.8 billion against total equity of KRW 127 billion, is one factor that helps explain that discount. Dividends are effectively absent.

Comparing the current position with the past trading band is most useful when read alongside the pace of earnings recovery. If profit recovers, earnings-based multiple comparisons become possible, but while the company is loss-making those comparisons are limited. The valuation hinges on the gap between asset-based and earnings-based readings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Owned microbiome CDMO capacity

The company operates 250 to 1,250-liter fermenters and a GMP plant dedicated to microbiome drugs. Past reports cited the small number of domestic microbiome CDMO operators as a point of differentiation. One-stop production from cell banking through drug product was also presented as a strength.

Profit turn in 2024

Operating profit turned positive at KRW 11 billion in 2024, with an operating margin of 6.4%. Operating cash flow was KRW 14 billion that year, showing a year in which core operations generated cash. The fourth quarter of 2025 also posted a quarterly operating profit of KRW 109 million.

Botulinum toxin pipeline and joint trial

Reports said the botulinum toxin candidate CKDB-501A received domestic Phase 3 IND clearance. A joint trial with Chinese partner CUTIA Therapeutics has been described as sharing clinical costs. If the toxin program completes clinical development, it could broaden the business structure beyond its current base.

09

Bear factors

Persistent losses and wider deficit

The company has posted five consecutive loss-making quarters from the third quarter of 2025 through the third quarter of 2026. The third-quarter 2026 operating loss of KRW 5.99 billion was wider than a year earlier, and the net loss attributable to controlling shareholders was KRW 10.5 billion. Net losses over the last four quarters total KRW 19 billion, with no clear timing yet for a return to profit.

Revenue decline and weaker probiotics

Revenue fell 6.8% to KRW 160.1 billion in 2025. Third-quarter 2026 revenue of KRW 29.3 billion was down 14.0% from a year earlier, extending the contraction in the top line. Whether CDMO revenue can fill the gap left by weaker probiotic sales is the open question.

Financial burden and unstable cash generation

The debt ratio was 136.0% at the end of 2025, with total liabilities of KRW 172.8 billion above total equity of KRW 127 billion. Operating cash flow swung back to an outflow of KRW 4.14 billion in 2025. Pursuing R&D and facility investment at the same time could raise the burden of funding.

10

Risk factors

CDMO contract execution risk

Microbiome CDMO work centers on early clinical samples from a small set of customers, so contract volumes can be uneven. If utilization stays low, fixed costs weigh directly on profit. Because overseas demand is central to this market, the pace of winning overseas customers is another variable.

Clinical pipeline uncertainty

The botulinum toxin candidate CKDB-501A is in Phase 3, and its value cannot be judged until results are available. The joint trial depends on the partner's pace of progress. The timing of clinical result disclosures is set by company announcements.

Financial structure and funding risk

With the debt ratio at 136.0% and operating cash flow negative in 2025, borrowing capacity could narrow. Total equity of about KRW 127 billion means cumulative losses would weaken the financial cushion. If facility investment and R&D proceed together, reliance on external funding could increase.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. Product-level sales and the R&D trend will show the drivers of the 2025 revenue decline and the size of the full-year 2026 operating loss.

  2. May 15, 2027

    Deadline for the first-quarter 2027 quarterly report. This is the point to check whether the run of five consecutive loss-making quarters ends and whether the operating loss narrows.

  3. Date not fixed (per company announcement)

    Progress of the Phase 3 trial for botulinum toxin CKDB-501A and results from the joint trial with Chinese partner CUTIA Therapeutics. These will inform the pipeline's value and the clinical cost-sharing structure.

12

Overall view

CKD Bio swung to an operating profit of KRW 11 billion in 2024, but operating profit fell to KRW 3.61 billion in 2025, and losses have run for five consecutive quarters through the third quarter of 2026.

The operating loss in the third quarter of 2026 was KRW 5.99 billion, and net losses attributable to controlling shareholders over the last four quarters total KRW 19 billion.

On the business side, the microbiome CDMO plant and GMP facility and the Phase 3-stage botulinum toxin candidate CKDB-501A are the axes of the transition.

The medium-term target of more than KRW 70 billion in annual revenue and the overseas expansion goal cited in past reports have not yet appeared in the disclosed results. On the financial side, the 136.0% debt ratio at the end of 2025 and the operating cash outflow stand out as burdens.

The next checkpoints are product-level sales and the R&D trend in the 2026 annual report, and whether the loss run ends in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. vegannews.co.kr
  2. dailypop.kr
  3. dailypharm.com
  4. vegannews.co.kr
  5. m.news.nate.com
  6. alphabiz.co.kr
  7. news.bizwatch.co.kr
  8. medifonews.com
  9. asiatoday.co.kr
  10. thefairnews.co.kr
  11. pinpointnews.co.kr
  12. comp.fnguide.com
  13. pharm.edaily.co.kr
  14. m.dailypharm.com
  15. pharm.edaily.co.kr
  16. mpharm.edaily.co.kr
  17. edaily.co.kr
  18. m.dailypharm.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis